18:27 , Dec 12, 2018 |  BC Extra  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...
13:05 , Dec 11, 2018 |  BC Extra  |  Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Tuesday with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant oncogenes...
13:03 , Dec 11, 2018 |  BC Innovations  |  Emerging Company Profile

Black Diamond: Mapping allostery

Black Diamond Therapeutics Inc. emerged from stealth on Tuesday with a platform to mine and drug baskets of allosteric mutant oncogenes using troves of human sequencing data that contain non-catalytic mutations previously deemed non-actionable. The...
03:38 , Dec 8, 2018 |  BioCentury  |  Finance

Moderna’s land grab

A blockbuster IPO by Moderna Inc. (NASDAQ:MRNA) gives the company the opportunity to make the case for mRNA. With more money, and a broader and more advanced pipeline than other players in the mRNA space,...
23:15 , Dec 7, 2018 |  BioCentury  |  Emerging Company Profile

ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer...
19:14 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Angina gene therapy company XyloCor raises $17M series A round

Gene therapy company XyloCor Therapeutics Inc. (Philadelphia, Pa.) raised $17 million Dec. 6 in a series A round led by Sofinnova Ventures and Life Science Partners. XyloCor’s lead candidate is XC001, a gene therapy that...
19:13 , Dec 7, 2018 |  BC Week In Review  |  Company News

Chi-Med, Innovent enter global cancer partnership

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) and Innovent Biologics Inc. (HKSE:1801) will take advantage of China’s new foreign data guidelines and enter into a global partnership to develop fruquintinib in combination with sintilimab to treat...
19:07 , Dec 7, 2018 |  BC Week In Review  |  Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
02:09 , Dec 7, 2018 |  BC Extra  |  Financial News

Moderna sets IPO record with upsized $604M offering

Brushing aside market volatility that has led several biotechs to miss their desired valuations in recent weeks, Moderna Inc. (NASDAQ:MRNA) raised $604.3 million in an upsized IPO late Thursday through the sale of 26.3 million...
23:31 , Dec 6, 2018 |  BC Extra  |  Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...